The sale of Coronil tablets of
Patanjali will not be allowed in Maharashtra without "proper certification", state Home Minister Anil Deshmukh said on Tuesday.
The statement came a day after the Indian Medical Association (IMA) expressed shock over the "blatant lie of WHO certification" for Coronil tablets which Patanjali claims is an evidence-based medicine to fight COVID-19.
While the IMA also demanded an explanation from Union Health Minister Harsh Vardhan in whose presence the medicine was launched, the World Health Organization clarified that it had not reviewed or certified the effectiveness of any traditional medicine for the treatment of COVID-19.
Without naming anyone, Deshmukh said on Twitter that it was "highly deplorable" that two senior Union ministers endorsed the drug.
"The #IMA has questioned the said 'clinical trials' of #Coronil & WHO refuted the false claims made by #Patanjali Ayurveda for giving any certificate regarding its effectiveness for #Covid19 treatment," Deshmukh said.
"...selling of #Coronil without proper certification from competent health organizations like #WHO, #IMA and others will not be allowed in Maharashtra," the minister said.
Yoga guru Ramdev's Patanjali Ayurved had on February 19 said the Coronil tablet had received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the WHO's certification scheme.
However, Patanjali's managing director Acharya Balkrishna later said "We want to clarify to avoid confusion that our WHO GMP compliant COPP certificate to Coronil is issued by DCGI, Government of India" and "WHO do not approve or disapprove any drugs".
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)